ProPhase Labs, Inc. (PRPH)
USD 0.3
(-2.27%)
USD 0.3
(-2.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 42.54 Million USD | 77.14% |
| 2022 | 24.01 Million USD | -21.68% |
| 2021 | 30.66 Million USD | 47.09% |
| 2020 | 20.84 Million USD | 1898.95% |
| 2019 | 1.04 Million USD | -75.36% |
| 2018 | 4.23 Million USD | 294.87% |
| 2017 | 1.07 Million USD | -84.33% |
| 2016 | 6.84 Million USD | 14.0% |
| 2015 | 6 Million USD | 12.34% |
| 2014 | 5.34 Million USD | 10.72% |
| 2013 | 4.82 Million USD | -7.41% |
| 2012 | 5.21 Million USD | -33.66% |
| 2011 | 7.85 Million USD | -4.64% |
| 2010 | 8.23 Million USD | 43.02% |
| 2009 | 5.75 Million USD | -12.69% |
| 2008 | 6.59 Million USD | -34.16% |
| 2007 | 10.01 Million USD | 8.26% |
| 2006 | 9.25 Million USD | -12.73% |
| 2005 | 10.6 Million USD | 10.75% |
| 2004 | 9.57 Million USD | 74.59% |
| 2003 | 5.48 Million USD | -15.8% |
| 2002 | 6.51 Million USD | 83.16% |
| 2001 | 3.55 Million USD | -26.65% |
| 2000 | 4.84 Million USD | -31.72% |
| 1999 | 7.1 Million USD | 77.5% |
| 1998 | 4 Million USD | -50.62% |
| 1997 | 8.1 Million USD | 3950.0% |
| 1996 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 49.6 Million USD | 9.82% |
| 2024 Q1 | 45.16 Million USD | 6.16% |
| 2023 Q2 | 31.8 Million USD | -10.25% |
| 2023 Q4 | 42.54 Million USD | 20.58% |
| 2023 Q1 | 35.43 Million USD | 47.53% |
| 2023 FY | 42.54 Million USD | 77.14% |
| 2023 Q3 | 35.28 Million USD | 10.95% |
| 2022 Q4 | 24.01 Million USD | -19.83% |
| 2022 FY | 24.01 Million USD | -21.68% |
| 2022 Q3 | 29.95 Million USD | 0.56% |
| 2022 Q2 | 29.78 Million USD | -10.33% |
| 2022 Q1 | 33.22 Million USD | 8.32% |
| 2021 Q1 | 32.77 Million USD | 57.22% |
| 2021 FY | 30.66 Million USD | 47.09% |
| 2021 Q4 | 30.66 Million USD | 25.86% |
| 2021 Q3 | 24.36 Million USD | -14.77% |
| 2021 Q2 | 28.59 Million USD | -12.78% |
| 2020 Q1 | 1.23 Million USD | 18.6% |
| 2020 Q3 | 12.27 Million USD | 728.63% |
| 2020 Q4 | 20.84 Million USD | 69.89% |
| 2020 FY | 20.84 Million USD | 1898.95% |
| 2020 Q2 | 1.48 Million USD | 19.73% |
| 2019 Q2 | 1.14 Million USD | 31.84% |
| 2019 Q1 | 870 Thousand USD | -79.45% |
| 2019 Q3 | 1.2 Million USD | 4.8% |
| 2019 Q4 | 1.04 Million USD | -13.23% |
| 2019 FY | 1.04 Million USD | -75.36% |
| 2018 Q3 | 876 Thousand USD | -45.08% |
| 2018 Q2 | 1.59 Million USD | 45.0% |
| 2018 Q1 | 1.1 Million USD | 2.61% |
| 2018 Q4 | 4.23 Million USD | 383.22% |
| 2018 FY | 4.23 Million USD | 294.87% |
| 2017 Q3 | 2.43 Million USD | -29.97% |
| 2017 FY | 1.07 Million USD | -84.33% |
| 2017 Q2 | 3.47 Million USD | -49.47% |
| 2017 Q1 | 6.87 Million USD | 0.48% |
| 2017 Q4 | 1.07 Million USD | -55.92% |
| 2016 Q2 | 5.17 Million USD | -11.22% |
| 2016 Q4 | 6.84 Million USD | 9.39% |
| 2016 Q3 | 6.25 Million USD | 20.78% |
| 2016 FY | 6.84 Million USD | 14.0% |
| 2016 Q1 | 5.83 Million USD | -2.82% |
| 2015 Q1 | 5.62 Million USD | 5.3% |
| 2015 FY | 6 Million USD | 12.34% |
| 2015 Q4 | 6 Million USD | 57.27% |
| 2015 Q3 | 3.81 Million USD | 3.75% |
| 2015 Q2 | 3.67 Million USD | -34.62% |
| 2014 Q4 | 5.34 Million USD | -27.65% |
| 2014 Q2 | 6.15 Million USD | 37.81% |
| 2014 Q1 | 4.46 Million USD | -7.46% |
| 2014 Q3 | 7.38 Million USD | 19.99% |
| 2014 FY | 5.34 Million USD | 10.72% |
| 2013 Q4 | 4.82 Million USD | -4.3% |
| 2013 Q3 | 5.04 Million USD | 5.66% |
| 2013 Q2 | 4.77 Million USD | 14.58% |
| 2013 Q1 | 4.16 Million USD | -20.08% |
| 2013 FY | 4.82 Million USD | -7.41% |
| 2012 FY | 5.21 Million USD | -33.66% |
| 2012 Q1 | 7.29 Million USD | -7.09% |
| 2012 Q2 | 6.4 Million USD | -12.24% |
| 2012 Q3 | 6.64 Million USD | 3.75% |
| 2012 Q4 | 5.21 Million USD | -21.57% |
| 2011 FY | 7.85 Million USD | -4.64% |
| 2011 Q1 | 7.35 Million USD | -10.65% |
| 2011 Q2 | 5.78 Million USD | -21.34% |
| 2011 Q3 | 7.57 Million USD | 30.86% |
| 2011 Q4 | 7.85 Million USD | 3.68% |
| 2010 Q2 | 6.36 Million USD | -3.08% |
| 2010 Q3 | 7.86 Million USD | 23.58% |
| 2010 Q1 | 6.56 Million USD | 13.98% |
| 2010 Q4 | 8.23 Million USD | 4.76% |
| 2010 FY | 8.23 Million USD | 43.02% |
| 2009 Q4 | 5.75 Million USD | -2.59% |
| 2009 Q2 | 5.52 Million USD | -8.78% |
| 2009 Q1 | 6.06 Million USD | -8.1% |
| 2009 Q3 | 5.91 Million USD | 6.92% |
| 2009 FY | 5.75 Million USD | -12.69% |
| 2008 Q3 | 6.83 Million USD | 1.34% |
| 2008 Q1 | 7.12 Million USD | -28.88% |
| 2008 Q2 | 6.74 Million USD | -5.27% |
| 2008 FY | 6.59 Million USD | -34.16% |
| 2008 Q4 | 6.59 Million USD | -3.57% |
| 2007 Q3 | 9.3 Million USD | 2.16% |
| 2007 FY | 10.01 Million USD | 8.26% |
| 2007 Q2 | 9.1 Million USD | 9.28% |
| 2007 Q1 | 8.33 Million USD | -9.94% |
| 2007 Q4 | 10.01 Million USD | 7.68% |
| 2006 Q2 | 5.81 Million USD | -26.4% |
| 2006 Q3 | 7.37 Million USD | 26.74% |
| 2006 Q4 | 9.25 Million USD | 25.5% |
| 2006 FY | 9.25 Million USD | -12.73% |
| 2006 Q1 | 7.9 Million USD | -25.46% |
| 2005 FY | 10.6 Million USD | 10.75% |
| 2005 Q4 | 10.6 Million USD | 24.82% |
| 2005 Q3 | 8.49 Million USD | 33.87% |
| 2005 Q2 | 6.34 Million USD | -26.58% |
| 2005 Q1 | 8.64 Million USD | -9.74% |
| 2004 Q4 | 9.57 Million USD | 154.69% |
| 2004 Q2 | 3.24 Million USD | -28.12% |
| 2004 Q1 | 4.5 Million USD | -17.77% |
| 2004 Q3 | 3.75 Million USD | 15.98% |
| 2004 FY | 9.57 Million USD | 74.59% |
| 2003 Q3 | 6.42 Million USD | 18.33% |
| 2003 Q1 | 5.25 Million USD | -19.33% |
| 2003 FY | 5.48 Million USD | -15.8% |
| 2003 Q2 | 5.43 Million USD | 3.41% |
| 2003 Q4 | 5.48 Million USD | -14.7% |
| 2002 Q1 | 2.86 Million USD | -19.29% |
| 2002 Q4 | 6.51 Million USD | 62.14% |
| 2002 Q3 | 4.01 Million USD | 33.11% |
| 2002 Q2 | 3.01 Million USD | 5.14% |
| 2002 FY | 6.51 Million USD | 83.16% |
| 2001 Q1 | 2.99 Million USD | -38.18% |
| 2001 Q2 | 2.89 Million USD | -3.45% |
| 2001 Q3 | 3.46 Million USD | 19.68% |
| 2001 Q4 | 3.55 Million USD | 2.68% |
| 2001 FY | 3.55 Million USD | -26.65% |
| 2000 Q4 | 4.84 Million USD | 18.53% |
| 2000 Q2 | 2.99 Million USD | -33.11% |
| 2000 Q1 | 4.47 Million USD | -36.97% |
| 2000 FY | 4.84 Million USD | -31.72% |
| 2000 Q3 | 4.08 Million USD | 36.62% |
| 1999 Q4 | 7.1 Million USD | 153.57% |
| 1999 Q3 | 2.8 Million USD | 55.56% |
| 1999 Q2 | 1.8 Million USD | -47.06% |
| 1999 FY | 7.1 Million USD | 77.5% |
| 1999 Q1 | 3.4 Million USD | -15.0% |
| 1998 Q2 | 1.9 Million USD | -52.5% |
| 1998 Q1 | 4 Million USD | -50.62% |
| 1998 Q3 | 3.6 Million USD | 89.47% |
| 1998 FY | 4 Million USD | -50.62% |
| 1998 Q4 | 4 Million USD | 11.11% |
| 1997 Q3 | 7.1 Million USD | 24.56% |
| 1997 Q1 | 12.6 Million USD | 793.62% |
| 1997 FY | 8.1 Million USD | 3950.0% |
| 1997 Q2 | 5.7 Million USD | -54.76% |
| 1997 Q4 | 8.1 Million USD | 14.08% |
| 1996 Q4 | 1.41 Million USD | 0.0% |
| 1996 FY | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 95.512% |
| Embecta Corp. | 2.03 Billion USD | 97.911% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 90.98% |
| Dynavax Technologies Corporation | 375.02 Million USD | 88.656% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 93.562% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 93.959% |
| PainReform Ltd. | 2.69 Million USD | -1480.974% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 74.044% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -592.944% |
| SCYNEXIS, Inc. | 55.45 Million USD | 23.275% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -362.605% |
| Cosmos Health Inc. | 30.25 Million USD | -40.63% |
| Journey Medical Corporation | 56.49 Million USD | 24.7% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -592.944% |
| Safety Shot Inc | 3.89 Million USD | -993.102% |
| Alpha Teknova, Inc. | 38.55 Million USD | -10.358% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 68.917% |
| Bright Green Corporation | 6.43 Million USD | -560.816% |
| Procaps Group, S.A. | 462.06 Million USD | 90.793% |
| Theratechnologies Inc. | 98.63 Million USD | 56.869% |
| Harrow Health, Inc. | 241.75 Million USD | 82.402% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -385.884% |
| Biofrontera Inc. | 23.13 Million USD | -83.863% |
| DURECT Corporation | 30.4 Million USD | -39.92% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 91.272% |
| Cronos Group Inc. | 43.73 Million USD | 2.726% |
| OptiNose, Inc. | 194.33 Million USD | 78.108% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 94.795% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 12.181% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -102.802% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 76.542% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -1027.85% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 18.989% |
| Radius Health, Inc. | 804.29 Million USD | 94.71% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -209.313% |
| Phibro Animal Health Corporation | 725.54 Million USD | 94.136% |
| Procaps Group S.A. | 462.06 Million USD | 90.793% |
| Alvotech | 1.88 Billion USD | 97.74% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -203.409% |
| Viatris Inc. | 27.21 Billion USD | 99.844% |
| Rockwell Medical, Inc. | 30.88 Million USD | -37.763% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 52.927% |
| SIGA Technologies, Inc. | 57.97 Million USD | 26.62% |
| Tilray Brands, Inc. | 892.11 Million USD | 95.231% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 80.644% |
| Shineco, Inc. | 47.6 Million USD | 10.625% |
| PetIQ, Inc. | 645.22 Million USD | 93.406% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -19281.173% |
| Incannex Healthcare Limited | 5.83 Million USD | -629.743% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 95.827% |
| Alimera Sciences, Inc. | 107.35 Million USD | 60.37% |
| Silver Spike Investment Corp. | 3 Million USD | -1313.501% |
| Assertio Holdings, Inc. | 148.41 Million USD | 71.335% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2143.923% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -99.589% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -505.522% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -401.076% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 75.463% |
| Hempacco Co., Inc. | 18.82 Million USD | -126.029% |
| Talphera, Inc. | 6.29 Million USD | -576.375% |
| Alvotech | 1.88 Billion USD | 97.74% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 75.351% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 94.906% |
| Currenc Group, Inc. | 177.67 Million USD | 76.055% |
| Kamada Ltd. | 109.96 Million USD | 61.312% |
| Indivior PLC | 1.95 Billion USD | 97.82% |
| Evoke Pharma, Inc. | 9.64 Million USD | -340.958% |
| Flora Growth Corp. | 17.22 Million USD | -147.033% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -401.076% |
| Evolus, Inc. | 209.68 Million USD | 79.711% |
| HUTCHMED (China) Limited | 536.38 Million USD | 92.068% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 95.129% |
| Akanda Corp. | 12.66 Million USD | -235.815% |